Table of contents

09 - Evidence Review Group report prepared by Southampton Health Technology Assessments Centre (SHTAC)

10 - Evidence Review Group response to company factual accuracy check

11 – Evidence Review Group report erratum

12 – Evidence Review Group additional analyses

13 – NICE specification letter to company requesting further work

14 – Company additional analyses from AbbVie

15 – Evidence Review Group commentary on company additional analyses

16 – Addendum to Evidence Review Group commentary on company additional analyses

17 – Marketing Authorisation clarification received from the European Medicines Agency (EMA)

18 – NHS England comments received on the ACD for ledipasvir-sofosbuvir for treating chronic hepatitis C

19 – NICE request to NHS England for clarification on hepatitis C drugs

20 – NHS England clarification response

21 – Consultee response – AbbVie

22 – Consultee response – The Hepatitis C Trust

23 – Consultee response - British HIV Association (BHIVA) and the British Association of Sexual Health and HIV (BASHH)

24 – Consultee response – The British Society of Gastroenterology (BSG), British Viral hepatitis Group (BVHG), British Association for the Study of the Liver (BASL) and Royal College of Pathologists

25 – Consultation response – Royal College of Physicians

26 – Consultee response – United Kingdom Clinical Pharmacy Association (UKCPA)

27 – Consultee response – Foundation for Liver Research

28 – Patient expert response from Gore